Syphilis Immunoassay Diagnostics Market to Record an Exponential CAGR by 2027
Advanced Analyzers Provide High-quality Solutions in Syphilis Immunoassay Diagnostics
New innovations in syphilis analyzers are becoming increasingly mainstream in the syphilis immunoassay diagnostics market. As such, companies are launching new technologies in analyzers. For instance, in April 2019, Gold Standard Diagnostics - a provider of comprehensive diagnostic solutions, revealed the launch of its proprietary technology with a U.S. patent, which performs serological testing for syphilis.
Advancements in analyzer technologies are creating incremental opportunities for healthcare companies in the syphilis immunoassay diagnostics market space. There is increasing demand for advanced analyzers in hospitals and blood banks due to increase in the spending capacity of patients with STDs. Companies in the syphilis immunoassay diagnostics market are innovating in new technologies with the help of dedicated machines to automate rapid plasma regain (RPR) assays. They are improving testing capabilities for laboratories with the help of new software developments to enhance outcomes in patients.
Novel approaches of technological automation and machine learning are being adopted to develop first-of-its-kind diagnostics systems. The combination of approaches is helping clinical laboratories offer high-quality solutions for syphilis testing.
To know the scope of our report Get a Sample on Syphilis Immunoassay Diagnostics Market
On-the-spot Testing Solutions Help Perform Immunoassays in ELISA
The growing trend of on-the-spot testing solutions has led to improvements in the syphilis immunoassay diagnostics landscape. For instance, clinical diagnostics company MBio, announced the launch of the LightDeck® platform, an innovative analytical technology that performs quantitative immunoassays and cell based assays. With the help of on-the-spot testing, companies in the syphilis immunoassay diagnostics market can tap into new business models, such as providing analytical testing services to the veterinary, food, military sectors.
Companies in the syphilis immunoassay diagnostics market are focused on expanding their product portfolios. They are increasing efforts to manufacture and sell instruments by acquiring licensing for the same. By these efforts, they are supporting the global OEM supply business model associated with various assays and their applications.
Healthcare industries are developing multiplexed immunoassay systems by experimenting on planar waveguide technology and fluorescence imaging. These efforts are being made to support outcomes in the ELISA (enzyme-linked immunosorbent assay) test, since ELISA currently accounts for the highest revenue in the syphilis immunoassay diagnostics market.
Get a glimpse of the in-depth analysis through our Report Brochure
PCR Gains Popularity as Non-invasive Specimen for Effective Diagnosis of Syphilis
Recent advancements in molecular biology have led to the popularity of molecular diagnosis, such as the polymerase chain reaction (PCR), in the syphilis immunoassay diagnostics ecosystem. PCR technology is playing a crucial role in diagnosing syphilis. Healthcare industries in the syphilis immunoassay diagnostics market are developing various PCR methodologies that can be easily adapted in the clinical and laboratory environment. PCR is being increasingly associated with widespread application and deep exploration in the healthcare space.
Fast developments in PCR have led to advancements in real-time PCR, nested PCR, and multiplex PCR. The high sensitivity and specificity of PCR is well-suited for the diagnosis of early-stage syphilis. On the other hand, routine PCR is well-received in secondary syphilis. Healthcare companies in the syphilis immunoassay diagnostics market are increasing R&D to detect atypical cases of vertebral, ocular, and tonsillar syphilis with the help of molecular biology. Real-time PCR is gaining increased popularity for its ability to calculate the sum of pathogens that reveal the severity of the infection.
Request the Coronavirus Impact Analysis across Industries and Markets - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2140
Companies Improve Access to Testing Technologies in LMICs to Prevent Maternal Syphilis
The issue of maternal and child mortality due to syphilis and HIV/AIDS is distinctly prevalent in low- and middle-income countries (LMICs). This is why, healthcare industries in the syphilis immunoassay diagnostics market are increasing efforts to improve child and maternal health through antenatal care.
At the same time, companies in the syphilis immunoassay diagnostics space are innovating in point of care diagnostic services. Although healthcare industries are making progress in the prevention of mother-to-child transmission, several new cases of pediatric infections are still being reported. Thus, companies in the syphilis immunoassay diagnostics market should improve access to new testing technologies that will reduce the incidence of syphilis infection in LMICs. Along with testing for syphilis, companies should offer convenient testing options such as the dual HIV/syphilis rapid diagnostics test to help patients assess the prevalence of any other bacterial infections.
Companies in the syphilis immunoassay diagnostics ecosystem are also increasing the availability of antenatal rapid syphilis testing in LMICs. Undiagnosed and untreated maternal syphilis has catalyzed the demand for antenatal rapid syphilis testing.
Expanding operations in future? To get the perfect launch ask for a custom report
More Trending Reports by Transparency Market Research –
Breast Pumps Market: globenewswire.com/news-release/2018/08/23/1555918/0/en/Breast-Pumps-Market-to-Rise-to-US-4-164-6-mn-by-2025-Says-TMR.html